Edgewise Therapeutics appoints Dr. Jonathan Fox to board of directors

Edgewise Therapeutics, Inc.

Dr. Jonathan Fox appointed as Class III director, term expiring at 2024 annual meeting.
He is President and CMO of BridgeBio Pharma and former CMO of MyoKardia, inventor of Camzyos.
Compensation includes $38k annual cash retainer, $4k for Nominating Committee, and stock option with ~$300k grant date fair value.
Company plans to advance EDG-7500 towards Phase 1 trial in HCM in H2 2023.
No arrangements or transactions requiring disclosure under Item 404(a).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Jonathan Fox

Director

EWTX · Edgewise Therapeutics, Inc.

Effective: 2023-03-02
Filed: March 6, 2023, 6:59 PM ET

On March 2, 2023, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Dr. Jonathan Fox to serve (i) as a Class III director, with a term expiring at the Company’s 2024 annual meeting of stockholders, and (ii) as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Jonathan Fox was appointed as Director at Edgewise Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 2, 2023, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Dr. Jonathan Fox to serve (i) as a Class III director, with a term expiring at the Company’s 2024 annual meeting of stockholders, and (ii) as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”).

View on SEC.gov

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-029022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.